Next Article in Journal
Genetic Modification of T Cells
Previous Article in Journal
Innate Lymphoid Cells in Tumor Immunity
Previous Article in Special Issue
Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy
Article Menu

Export Article

Open AccessReview
Biomedicines 2016, 4(2), 8;

Prospects for Foamy Viral Vector Anti-HIV Gene Therapy

Pharmaceutical Sciences, College of Pharmacy, Washington State University Spokane, Spokane, WA 99202, USA
School of Molecular Biosciences, Washington State University, Pullman, WA 99164, USA
Author to whom correspondence should be addressed.
Academic Editor: Kenneth Cornetta
Received: 29 January 2016 / Revised: 18 March 2016 / Accepted: 23 March 2016 / Published: 29 March 2016
(This article belongs to the Special Issue Gene Therapy Strategies for HIV/AIDS)
Full-Text   |   PDF [1001 KB, uploaded 29 March 2016]   |  


Stem cell gene therapy approaches for Human Immunodeficiency Virus (HIV) infection have been explored in clinical trials and several anti-HIV genes delivered by retroviral vectors were shown to block HIV replication. However, gammaretroviral and lentiviral based retroviral vectors have limitations for delivery of anti-HIV genes into hematopoietic stem cells (HSC). Foamy virus vectors have several advantages including efficient delivery of transgenes into HSC in large animal models, and a potentially safer integration profile. This review focuses on novel anti-HIV transgenes and the potential of foamy virus vectors for HSC gene therapy of HIV. View Full-Text
Keywords: gene therapy; retroviral vector; foamy viruses; anti-HIV transgenes gene therapy; retroviral vector; foamy viruses; anti-HIV transgenes

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Nalla, A.K.; Trobridge, G.D. Prospects for Foamy Viral Vector Anti-HIV Gene Therapy. Biomedicines 2016, 4, 8.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top